Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
-0.93 (-1.16%)
4:11:40 PM EDT: $78.79 -0.11 (-0.14%)

Merck Announces Week 96 Data From Phase 2B Study Evaluating Islatravir In Combination With Doravirine In Adults With Hiv1 Infection

Published: 10/08/2020 11:06 GMT
Merck & Co Inc (MRK) - Merck Announces Week 96 Data From Phase 2b Study Evaluating Islatravir in Combination With Doravirine in Adults With Hiv-1 Infection.
Merck & Co Inc - Treatment With Islatravir and Doravirine Maintained Viral Suppression and No Viral Resistance Was Identified.
Merck & Co Inc - Presenting Phase 1/1b Results for Mk-8507, a New Investigational Once-weekly Oral Hiv Agent; Company Advances Mk-8507 to Phase 2.
Merck & Co Inc - Week 96 Findings Demonstrated That Combination of Islatravir and Doravirine Maintained Virologic Suppression.
Merck - Lower Rate of Drug-related Adverse Events (aes) Occurred in Islatravir Groups (7.8%) Compared With Delstrigo Group (22.6%) at Week 96.